Core Viewpoint - Merus N.V. has announced a public offering of 5,263,158 common shares priced at $57.00 per share, aiming to raise approximately $300 million in gross proceeds to support its oncology product development and general corporate purposes [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 789,473 common shares [1]. - The expected closing date for the offering is around June 5, 2025, pending customary closing conditions [2]. - The offering is conducted under a shelf registration statement filed with the SEC, effective since February 28, 2024 [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for advancing clinical development of product candidates, preclinical research, technology development, and general corporate purposes [2]. Group 3: Underwriters - Jefferies, BofA Securities, Leerink Partners, Guggenheim Securities, Truist Securities, and LifeSci Capital are serving as joint book-running managers for the offering, with Van Lanschot Kempen as the lead manager [3]. Group 4: Company Overview - Merus N.V. specializes in developing innovative full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics, which exhibit features similar to conventional human monoclonal antibodies [12].

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Thursday, May 15, 2025 at 8:40 a.m. PT/11:40 a.m. ET. The webcast of the presentation will be contemporaneously availa ...

Core Viewpoint - Merus N.V. is set to participate in the 24th Annual Needham Virtual Healthcare Conference, highlighting its focus on innovative oncology treatments [1]. Company Overview - Merus is an oncology company specializing in the development of full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics [3]. - Multiclonics are produced using industry-standard processes and have demonstrated characteristics similar to conventional human monoclonal antibodies, including long half-life and low immunogenicity in preclinical and clinical studies [3]. Event Details - Bill Lundberg, M.D., President and CEO of Merus, will engage in a fireside chat at the conference on April 8, 2025, at 8:45 a.m. ET [1]. - The presentation will be available via webcast on the company's Investors page, with an archived version accessible for a limited time post-event [2].